VITRAKVI 25 mg, hard capsule 56 capsules
Active ingredients: Larotrectinib, Larotrectinib sulfate
Commercialized according to BDPMDispensing in France: Prescription only
Hard capsule56 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- VITRAKVI 25 mg, gélule
- Pharmaceutical form
- gélule
- Route of administration
- orale
- Presentation description
- 1 flacon(s) polyéthylène haute densité (PEHD) avec fermeture de sécurité enfant de 56 gélule(s)
- Marketing authorisation holder
- BAYER AG (ALLEMAGNE)
- Reimbursement according to BDPM
- 100%
- Reimbursement conditions
- Ce médicament peut être pris en charge ou remboursé par l'Assurance Maladie dans les cas suivants :<br><br>- fibrosarcome infantile ou d'autres sarcomes pédiatriques des tissus mous (qui sont des cancers qui touchent les parties de l'organisme qu'on appelle tissus mous, comme par exemple la graisse ou les muscles) ; JOURNAL OFFICIEL ; 20/11/20
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 27 Aug 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
67022406CIP73018799CIP133400930187999Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LAROTRECTINIBgélule | 25 mg · une gélule | FT |
| SULFATE DE LAROTRECTINIBgélule | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.